These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 26870808)

  • 1. Prediction of Cancer Prevention: From Mammogram Screening to Identification of BRCA1/2 Mutation Carriers in Underserved Populations.
    Robinson LS; Hendrix A; Xie XJ; Yan J; Pirzadeh-Miller S; Pritzlaff M; Read P; Pass S; Euhus D; Ross TS
    EBioMedicine; 2015 Nov; 2(11):1827-33. PubMed ID: 26870808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
    Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
    Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical implications of genetic testing for BRCA1 and BRCA2 mutations in Austria.
    Singer CF; Muhr D; Rappaport C; Tea MK; Gschwantler-Kaulich D; Fink-Retter A; Pfeiler G; Berger A; Sun P; Narod SA
    Clin Genet; 2014 Jan; 85(1):72-5. PubMed ID: 23772696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identifying Women at Risk for Hereditary Breast and Ovarian Cancer Syndrome Utilizing Breast Care Nurse Navigation at Mammography and Imaging Centers.
    Appel SJ; Cleiment RJ
    J Natl Black Nurses Assoc; 2015 Dec; 26(2):17-26. PubMed ID: 27045154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Current clinical issues and recent trends in hereditary breast and ovarian cancer in Japan-genetic testing for HBOC and risk-reducing surgery].
    Arai M; Iwase T; Takazawa Y; Takeshima N
    Gan To Kagaku Ryoho; 2014 Nov; 41(11):1333-9. PubMed ID: 25434434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening of BRCA1/2 genes mutations and copy number variations in patients with high risk for hereditary breast and ovarian cancer syndrome (HBOC).
    El Ansari FZ; Jouali F; Marchoudi N; Bennani MM; Ghailani NN; Barakat A; Fekkak J
    BMC Cancer; 2020 Aug; 20(1):747. PubMed ID: 32778078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast cancer detection among Irish BRCA1 & BRCA2 mutation carriers: a population-based study.
    Walsh EM; Farrell MP; Nolan C; Gallagher F; Clarke R; McCaffrey JA; Kennedy MJ; Barry M; Kell MR; Gallagher DJ
    Ir J Med Sci; 2016 Feb; 185(1):189-94. PubMed ID: 25673166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High prevalence of BRCA1 founder mutations in Greek breast/ovarian families.
    Konstantopoulou I; Tsitlaidou M; Fostira F; Pertesi M; Stavropoulou AV; Triantafyllidou O; Tsotra E; Tsiftsoglou AP; Tsionou C; Droufakou S; Dimitrakakis C; Fountzilas G; Yannoukakos D
    Clin Genet; 2014 Jan; 85(1):36-42. PubMed ID: 24010542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rates of risk-reducing surgery in Israeli BRCA1 and BRCA2 mutation carriers.
    Laitman Y; Vaisman Y; Feldman D; Helpman L; Gitly M; Paluch Shimon S; Berger R; Cohen L; Narod SA; Friedman E
    Clin Genet; 2014 Jan; 85(1):68-71. PubMed ID: 23517234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health Care Disparities in Hereditary Ovarian Cancer: Are We Reaching the Underserved Population?
    Randall TC; Armstrong K
    Curr Treat Options Oncol; 2016 Aug; 17(8):39. PubMed ID: 27315065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.
    Casey MJ; Bewtra C; Hoehne LL; Tatpati AD; Lynch HT; Watson P
    Gynecol Oncol; 2000 Sep; 78(3 Pt 1):278-87. PubMed ID: 10985881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-risk breast cancer surveillance with MRI: 10-year experience from the German consortium for hereditary breast and ovarian cancer.
    Bick U; Engel C; Krug B; Heindel W; Fallenberg EM; Rhiem K; Maintz D; Golatta M; Speiser D; Rjosk-Dendorfer D; Lämmer-Skarke I; Dietzel F; Schäfer KWF; Leinert E; Weigel S; Sauer S; Pertschy S; Hofmockel T; Hagert-Winkler A; Kast K; Quante A; Meindl A; Kiechle M; Loeffler M; Schmutzler RK;
    Breast Cancer Res Treat; 2019 May; 175(1):217-228. PubMed ID: 30725383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preventing breast and ovarian cancers in high-risk BRCA1 and BRCA2 mutation carriers.
    Collins IM; Milne RL; Weideman PC; McLachlan SA; Friedlander ML; ; Hopper JL; Phillips KA
    Med J Aust; 2013 Nov; 199(10):680-3. PubMed ID: 24237098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A model for estimating ovarian cancer risk: application for preventive oophorectomy.
    Giannakeas V; Sopik V; Shestopaloff K; Iqbal J; Rosen B; Akbari M; Narod SA
    Gynecol Oncol; 2015 Nov; 139(2):242-7. PubMed ID: 26341709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic and clinical characteristics in Japanese hereditary breast and ovarian cancer: first report after establishment of HBOC registration system in Japan.
    Arai M; Yokoyama S; Watanabe C; Yoshida R; Kita M; Okawa M; Sakurai A; Sekine M; Yotsumoto J; Nomura H; Akama Y; Inuzuka M; Nomizu T; Enomoto T; Nakamura S
    J Hum Genet; 2018 Apr; 63(4):447-457. PubMed ID: 29176636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increasing referral of at-risk women for genetic counseling and BRCA testing using a screening tool in a community breast imaging center.
    Arun BK; Peterson SK; Sweeney LE; Bluebond RD; Tidwell RSS; Makhnoon S; Kushwaha AC
    Cancer; 2022 Jan; 128(1):94-102. PubMed ID: 34424535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mammographic density and breast cancer in women from high risk families.
    Ramón Y Cajal T; Chirivella I; Miranda J; Teule A; Izquierdo Á; Balmaña J; Sánchez-Heras AB; Llort G; Fisas D; Lope V; Hernández-Agudo E; Juan-Fita MJ; Tena I; Robles L; Guillén-Ponce C; Pérez-Segura P; Luque-Molina MS; Hernando-Polo S; Salinas M; Brunet J; Salas-Trejo MD; Barnadas A; Pollán M
    Breast Cancer Res; 2015 Jul; 17(1):93. PubMed ID: 26163143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Characteristics of selected clinical features in BRCA1 mutation carriers affected with breast cancer undergoing preventive female genital tract surgeries].
    Menkiszak J; Chudecka-Głaz A; Gronwald J; Bedner R; Cymbaluk-Płoska A; Wezowska M; Zielińska D; Rzepka-Górska I
    Ginekol Pol; 2013 Sep; 84(9):758-64. PubMed ID: 24191513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study.
    Fostira F; Tsitlaidou M; Papadimitriou C; Pertesi M; Timotheadou E; Stavropoulou AV; Glentis S; Bournakis E; Bobos M; Pectasides D; Papakostas P; Pentheroudakis G; Gogas H; Skarlos P; Samantas E; Bafaloukos D; Kosmidis PA; Koutras A; Yannoukakos D; Konstantopoulou I; Fountzilas G
    Breast Cancer Res Treat; 2012 Jul; 134(1):353-62. PubMed ID: 22434525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experience of risk-reducing salpingo-oophorectomy for a BRCA1 mutation carrier and establishment of a system performing a preventive surgery for hereditary breast and ovarian cancer syndrome in Japan: our challenges for the future.
    Hirasawa A; Masuda K; Akahane T; Tsuruta T; Banno K; Makita K; Susumu N; Jinno H; Kitagawa Y; Sugano K; Kosaki K; Aoki D
    Jpn J Clin Oncol; 2013 May; 43(5):515-9. PubMed ID: 23487443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.